4.6 Article

Whole Exome Sequencing in Coloboma/Microphthalmia: Identification of Novel and Recurrent Variants in Seven Genes

Journal

GENES
Volume 12, Issue 1, Pages -

Publisher

MDPI
DOI: 10.3390/genes12010065

Keywords

whole-exome sequencing; microphthalmia; coloboma; genetic screening; MAC; ocular development; anterior segment dysgenesis

Funding

  1. Iten-Kohaut Foundation
  2. University Hospital Zurich Foundation

Ask authors/readers for more resources

Coloboma and microphthalmia (C/M) are related congenital eye malformations that exhibit significant genetic heterogeneity, as revealed by a study utilizing high throughput DNA sequencing technologies. The study identified novel gene variants and potentially disease-causing genes in a portion of C/M patients, including three de novo mutations. This highlights the diagnostic power of whole-exome sequencing for genetic screening in patients and families with C/M.
Coloboma and microphthalmia (C/M) are related congenital eye malformations, which can cause significant visual impairment. Molecular diagnosis is challenging as the genes associated to date with C/M account for only a small percentage of cases. Overall, the genetic cause remains unknown in up to 80% of patients. High throughput DNA sequencing technologies, including whole-exome sequencing (WES), are therefore a useful and efficient tool for genetic screening and identification of new mutations and novel genes in C/M. In this study, we analyzed the DNA of 19 patients with C/M from 15 unrelated families using singleton WES and data analysis for 307 genes of interest. We identified seven novel and one recurrent potentially disease-causing variants in CRIM1, CHD7, FAT1, PTCH1, PUF60, BRPF1, and TGFB2 in 47% of our families, three of which occurred de novo. The detection rate in patients with ocular and extraocular manifestations (67%) was higher than in patients with an isolated ocular phenotype (46%). Our study highlights the significant genetic heterogeneity in C/M cohorts and emphasizes the diagnostic power of WES for the screening of patients and families with C/M.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available